Travelan® is an over the counter supplement that can be taken to reduce the risk of travellers' diarrhoea (Bali Belly, Montezuma's Revenge) and reduce the symptoms of minor gastrointestinal disorders....
Protectyn® has been scientifically formulated to help maintain healthy digestive function and support the liver....
Fully protected by Incapsula
Join our social networks
Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle.
The company presently has three drug candidates in clinical development and several in early stage preclinical development. Immuron believes its therapeutic drug candidates have the potential to transform the existing treatment paradigms for moderate to severe Campylobacteriosis, recurrent Clostridiodes difficile (C.difficle) infections, Enterotoxigenic Escherichia coli (ETEC) infections, Shigellosis (Bacillary dysentery) and travelers’ diarrhea.
